Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys:: Relationship to anticataleptic effect

被引:18
|
作者
Milhara, Takuma [1 ]
Noda, Akihiro [2 ]
Arai, Hiroshi [3 ]
Mihara, Kayoko [1 ]
Iwashita, Akinori [1 ]
Murakami, Yoshihiro [2 ]
Matsuya, Takahiro [2 ]
Miyoshi, Sosuke [2 ]
Nishimura, Shintaro [2 ]
Matsuoka, Nobuya [1 ]
机构
[1] Astellas Pharma Inc, Pharmacol Res Labs, Tsukuba, Ibaraki 3058585, Japan
[2] Astellas Pharma Inc, Appl Pharmacol Res Labs, Tsukuba, Ibaraki 3058585, Japan
[3] Astellas Pharma Inc, Drug Metab Res Labs, Tokyo, Japan
关键词
PET; ASP5854; C-11-SCH442416; catalepsy; adenosine A(2A) receptors;
D O I
10.2967/jnumed.108.051474
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The purpose of the present study was to measure adenosine A(2A) receptor (A(2A)R) occupancy in the brain by a novel adenosine A(1)/A(2A) antagonist, 5-[5-amino-3-(4fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), and to determine the degree of receptor occupancy necessary to inhibit haloperidol-induced catalepsy in rhesus monkeys. Methods: A(2A)R occupancy by ASP5854 (0.001-0.1 mg/kg) was examined in the striatum using an A(2A)R-specific radiotracer, C-11-SCH442416, and PET in conscious rhesus monkeys. A(2A)R occupancy was monitored after a single intravenous administration of ASP5854 in 3 animals, and a dynamic PET scan was performed at 1, 4, and 8 h after an intravenous bolus injection of the tracer for approximately 740 MBq. Catalepsy was induced by haloperidol (0.03 mg/kg, intramuscularly) and examined for incidence and duration. Results: ASP5854 dose-dependently increased A2AR occupancy in the striatum and showed long-lasting occupancy even after the reduction of plasma concentration. Haloperidol induced severe catalepsy at 40 min after intramuscular injection. The incidence and duration of cataleptic posture were dose-dependently reduced by ASP5854 at 1 h after oral administration, and the minimum ED50 value was 0.1 mg/kg. Administration of a dose of 0.1 mg/kg yielded a plasma concentration of 97 +/- 16.3 ng/mL, which corresponded to 85%-90% of A(2A)R occupancy. Conclusion: These results showed that ASP5854 antagonized A(2A)R in the striatum, and the dissociation from A(2A)R was relatively slow. In addition, more than 85% A(2A)R occupancy by ASP5854 resulted in an inhibition of haloperidol-induced catalepsy. Thus, such a pharmacodynamic study directly demonstrates both the kinetics of a drug in the brain and the relationship between dose-dependent receptor occupancy and plasma level.
引用
收藏
页码:1183 / 1188
页数:6
相关论文
共 50 条
  • [21] Selective A2A, but not A1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats
    Villanueva-Toledo, J
    Moo-Puc, RE
    Góngora-Alfaro, JL
    NEUROSCIENCE LETTERS, 2003, 346 (1-2) : 1 - 4
  • [22] The regulation of circadian entrainment in mice by the adenosine the A2A/A1 receptor antagonist CT1500
    Jagannath, Aarti
    Di Pretoro, Simona
    Ebrahimjee, Farid
    Ftouni, Suzanne
    Taylor, Lewis
    Foster, Russell G.
    Vasudevan, Sridhar
    FRONTIERS IN PHYSIOLOGY, 2022, 13
  • [23] Novel approaches for targeting the adenosine A2A receptor
    Yuan, Gengyang
    Gedeon, Nicholas G.
    Jankins, Tanner C.
    Jones, Graham B.
    EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (01) : 63 - 80
  • [24] Benzopyrone represents a privilege scaffold to identify novel adenosine A1/A2A receptor antagonists
    van der Walt, Mietha M.
    Terre'Blanche, Gisella
    BIOORGANIC CHEMISTRY, 2018, 77 : 136 - 143
  • [25] A1 and A2a adenosine receptor gene expression during cardiovascular aging
    Perlini, S
    Arosio, B
    Palladini, G
    Vergani, C
    Annoni, G
    Ferrari, AU
    EUROPEAN HEART JOURNAL, 2002, 23 : 446 - 446
  • [26] Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease
    Jenner, P
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (06) : 729 - 738
  • [27] Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist:: Role of A2A receptor and Erk1/2
    Kis, A
    Baxter, GF
    Yellon, DM
    CARDIOVASCULAR DRUGS AND THERAPY, 2003, 17 (5-6) : 415 - 425
  • [28] Limitation of Myocardial Reperfusion Injury by AMP579, an Adenosine A1/A2A Receptor Agonist: Role of A2A Receptor and Erk1/2
    Adrienn Kis
    Gary F. Baxter
    Derek M. Yellon
    Cardiovascular Drugs and Therapy, 2003, 17 : 415 - 425
  • [29] Clinical/Pharmacological Aspect of Adenosine A2A Receptor Antagonist for Dyskinesia
    Kanda, Tomoyuki
    Uchida, Shin-ichi
    ADENOSINE RECEPTORS IN NEUROLOGY AND PSYCHIATRY, 2014, 119 : 127 - 150
  • [30] Adenosine A2A receptor antagonist treatment of Parkinson's disease
    Bara-Jimenez, W
    Sherzai, A
    Dimitrova, T
    Favit, A
    Bibbiani, F
    Gillespie, M
    Morris, MJ
    Mouradian, MM
    Chase, TN
    NEUROLOGY, 2003, 61 (03) : 293 - 296